Reset filter
Mots-clés
Presión Sanguínea ×
Afficher plus Mots-clés
Table des matières
  1. 1. Essai clinique
  2. 2. Routinedokumentation
  3. 3. Études de registres/cohortes
  4. 4. Assurance qualité
  5. 5. Standard de données
  6. 6. Questionnaire pour les patients
  7. 7. Spécialité médicale
Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

81 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Visit 9 (24 Months) Ponderosa CML ZKSJ0083 - Visit 9 (24 Months)

- 20/03/2016 - 1 Formulaire, 5 Groupes Item, 61 Eléments de données, 1 Langue
Groupes Item: Patient status, Blood pressure, Laboratory parameters, Treatment, Treatment Response
Study part: Visit 9 (24 Months).Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

Cancellation Visits Ponderosa CML ZKSJ0083 - Cancellation Visits

- 20/03/2016 - 1 Formulaire, 5 Groupes Item, 61 Eléments de données, 1 Langue
Groupes Item: Patient status, Blood pressure, Laboratory parameters, Treatment, Treatment Response
Study part: Cancellation Visits.Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

Visit 3 (6 Months) Ponderosa CML ZKSJ0083 - Visit 3 (6 Months)

- 20/03/2016 - 1 Formulaire, 5 Groupes Item, 61 Eléments de données, 1 Langue
Groupes Item: Patient status, Blood pressure, Laboratory parameters, Treatment, Treatment Response
Study part: Visit 3 (6 Months).Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

Visit 4 (9 Months) Ponderosa CML ZKSJ0083 - Visit 4 (9 Months)

- 20/03/2016 - 1 Formulaire, 5 Groupes Item, 61 Eléments de données, 1 Langue
Groupes Item: Patient status, Blood pressure, Laboratory parameters, Treatment, Treatment Response
Study part: Visit 4 (9 Months).Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

Visit 7 (18 Months) Ponderosa CML ZKSJ0083 - Visit 7 (18 Months)

- 20/03/2016 - 1 Formulaire, 5 Groupes Item, 61 Eléments de données, 1 Langue
Groupes Item: Patient status, Blood pressure, Laboratory parameters, Treatment, Treatment Response
Study part: Visit 7 (18 Months).Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

Visit 5 (12 Months) Ponderosa CML ZKSJ0083 - Visit 5 (12 Months)

- 20/03/2016 - 1 Formulaire, 5 Groupes Item, 61 Eléments de données, 1 Langue
Groupes Item: Patient status, Blood pressure, Laboratory parameters, Treatment, Treatment Response
Study part: Visit 5 (12 Months).Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

Visit 6 (15 Months) Ponderosa CML ZKSJ0083 - Visit 6 (15 Months)

- 20/03/2016 - 1 Formulaire, 5 Groupes Item, 61 Eléments de données, 1 Langue
Groupes Item: Patient status, Blood pressure, Laboratory parameters, Treatment, Treatment Response
Study part: Visit 6 (15 Months).Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

Visit 8 (21 Months) Ponderosa CML ZKSJ0083 - Visit 8 (21 Months)

- 20/03/2016 - 1 Formulaire, 5 Groupes Item, 61 Eléments de données, 1 Langue
Groupes Item: Patient status, Blood pressure, Laboratory parameters, Treatment, Treatment Response
Study part: Visit 8 (21 Months).Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

Visit 2 (3 Months) Ponderosa CML ZKSJ0083 - Visit 2 (3 Months)

- 20/03/2016 - 1 Formulaire, 5 Groupes Item, 61 Eléments de données, 1 Langue
Groupes Item: Patient status, Blood pressure, Laboratory parameters, Treatment, Treatment Response
Study part: Visit 2 (3 Months).Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial